Bayer: Science For A Better Life - research

Recent studies confirm: active ingredient of Aspirin® can protect against colorectal cancer

High-potential multitalent

1/3Go to image Suche

Aspirin® tablets are manufactured in modern production facilities in Bitterfeld, Germany.

Acetylsalicylic acid (ASA) – the active ingredient in Aspirin® – is capable of much more than just relieving pain, inflammation and fever. It has been known for some time that regular administration of ASA also reduces the likelihood of myocardial infarction and stroke. According to the findings of a long-term U.S. study, regular use of ASA may also reduce the risk of colorectal cancer.

Long-term ASA use may reduce the risk of colorectal cancer

Colorectal cancer is one of the most common forms of cancer. Lifestyles in the Western industrialized countries pose a particular risk, but a familial predisposition, inflammatory bowel disease and proliferating intestinal growths are also regarded as risk factors. The effects of ASA have been evaluated in a study involving more than 80,000 nurses over a period of 20 years. Scientists observed that the risk of colorectal cancer dropped by 23 percent on average. The following article relates how the active ingredient in Aspirin® can help in such cases, what dose is considered to be the most promising and what other risks exist.